Analysis of the effects of simegallutide in obese T2DM patients with essential hypertension

FANG Pingting; ZENG Lijuan; MA Qinghua

Abstract：Objective:To study the effect of simegallutide in patients with type 2 diabetes mellitus(T2DM)with o-besity and essential hypertension.Methods:All 90 patients with T2DM,obesity,and primary hypertension from the 73rd group military hospital of the army from September 2021 to September 2022 were selected as the study subjects and randomly divided into a control group(n=45)and an observation group(n=45)according to the random number table method.The control group was treated with routine treatment to control blood sugar,and the observation group was treated with simeglutide on the basis of the control group.The changes of blood glucose,islet cell function,blood pressure,BMI and adverse reactions were observed.Results:After treatment,the levels of fasting plasma glucose(FPG),2 hour postprandial plasma glucose(2 h PG),Glycated hemoglobin acid(HbAlC),triglyceride acid(TG),ser-um cholesterol(TC),diastolic blood pressure(DBP),systolic blood pressure(SBP)and body mass index(BMI)in both groups were lower than those before treatment,and the observation group was lower than the control group,the difference was statistically significant(P＜0.05).After treatment,the higher insulin resistance index(HOMA-IR)in the two groups was lower than that before treatment,and the HOMA-IR in the observation group was lower than that in the control group(P＜0.05).After treatment,the level of islet β-cell function index(HOMA-β)in the two groups was higher than that before treatment,and the observation group was higher than that in the control group,the differ-ence was statistically significant(P＜0.05).Conclusion:The adjuvant treatment of T2DM patients with obesity and HT can effectively control blood glucose,blood pressure and BMI,and improve islet cell function without increasing the occurrence of adverse effects.